Document is current
Any future updates will be listed below
-
Authors
Abdallah, C G
Wrocklage, K M
Averill, C L
Akiki, T
Schweinsburg, B
Roy, A
Martini, B
Southwick, S M
Krystal, J H
Scott, J C
- License Information
-
More Information
Article History
Received: 22 December 2016
Accepted: 30 December 2016
First Online: 28 February 2017
Competing interests
: CGA has served as consultant and/or on advisory boards for Genentech and Janssen. JHK is a consultant for AbbVie, Amgen, Astellas Pharma Global Development, AstraZeneca Pharmaceuticals, Biomedisyn Corporation, Bristol-Myers Squibb, Eli Lilly and Company, Euthymics Bioscience, Neurovance, FORUM Pharmaceuticals, Janssen Research & Development, Lundbeck Research USA, Novartis Pharma AG, Otsuka America Pharmaceutical, Sage Therapeutics, Sunovion Pharmaceuticals and Takeda Industries; is on the Scientific Advisory Board for Lohocla Research Corporation, Mnemosyne Pharmaceuticals, Naurex and Pfizer; is a stockholder in Biohaven Medical Sciences; holds stock options in Mnemosyne Pharmaceuticals; holds patents for Dopamine and Noradrenergic Reuptake Inhibitors in Treatment of Schizophrenia, US Patent No. 5,447,948 (issued 5 September 1995), and Glutamate Modulating Agents in the Treatment of Mental Disorders, US Patent No. 8778979 (issued 15 July 2014); and filed a patent for Intranasal Administration of Ketamine to Treat Depression, US Application No. 14/197767 (filed on 5 March 2014); US application or Patent Cooperation Treaty international application No. 14/306382 (filed on 17 June 2014). The remaining authors declare no conflict of interest.
